Skip to main content

A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera


Ropeginterferon alfa-2b represents a new-generation pegylated interferon-based therapy and is administered every 2–4 weeks. It is approved for polycythemia vera (PV) treatment in the United States and Europe with a starting dose of 100 µg (50 µg for patients receiving hydoxyurea) and intra-patient dose titrations up to 500 µg at 50 µg increments, which took approximately 20 or more weeks to reach a plateau dose level. This study aimed to assess ropeginterferon alfa-2b at an alternative dosing regimen with a higher starting dose and quicker intra-patient dose titrations, i.e., the 250–350–500 μg schema, in 49 Chinese patients with PV with resistance or intolerance to hydroxyurea. The primary endpoint of the complete hematologic response rate at treatment weak 24 was 61.2%, which was notably higher than 43.1% at 12 months with the approved dosing schema. The JAK2V617F allele burden decreased from baseline to week 24 (17.8% ± 18.0%), with one patient achieving a complete molecular response. Ropeginterferon alfa-2b was well-tolerated and most adverse events (AEs) were mild or moderate. Common AEs included alanine aminotransferase and aspartate aminotransferase increases mostly at grade 1 or 2 levels. Patients did not present with jaundice or significant bilirubin level increase. No grade 4 or 5 AEs occurred. Seven patients (14.3%) experienced reversible, drug-related grade 3 AEs. No AEs led to treatment discontinuation. Ropeginterferon alfa-2b at the 250–350–500 μg regimen is highly effective and well-tolerated and can help patients achieve greater and rapid complete hematologic and molecular responses.

Clinical Trial Registration: This trial is registered at (Identifier: NCT05485948) and in China (China National Medical Products Administration Registration Number: CTR20211664).

To the Editor

Patients with Polycythemia vera (PV) are at an increased risk of developing thromboembolic events due to increased blood cell counts and have a long-term risk of neoplastic progression to myelofibrosis or acute myeloid leukemia [1]. Ropeginterferon alfa-2b represents a new-generation pegylated interferon (IFN)-based therapy [2,3,4,5,6,7]. It has been approved for the treatment of PV in the United States, Europe, and other countries or regions, including Macao, China. Ropeginterferon alfa-2b is used at a starting dose of 100 µg [or 50 µg for patients under hydroxyurea (HU) treatment], with intra-patient dose increments of 50 µg to a maximum recommended dose of 500 µg [8]. It comprises multiple steps and could take up to more than 20 weeks to reach the plateau dose level [8, 9]. This current study aimed to assess whether ropeginterferon alfa-2b treatment at a starting dose of 250 µg, followed by 350 µg two weeks later and then 500 µg from week 4 onwards, i.e., the 250–350–500 µg dosing regimen, could achieve rapid and good clinical efficacy with tolerability within 24 weeks of treatment.

This study enrolled 49 patients. One patient withdrew consent during the study and 48 patients completed the 24-week treatment according to protocol. The mean patient age at enrolment was 53 years. All patients had previously received HU and were intolerant to HU. More than half of the patients (61.2%) received prior IFN therapy. Patients with prior IFN treatment needed to have a wash-out time of at least 14 days and were negative for ropeginterferon alfa-2b binding antibodies [10]. The primary end point of the study, namely the complete hematologic response (CHR) rate at week 24 without the need for phlebotomy or erythrocyte apheresis in the preceding 3 months, and its 95% confidence interval (CI) was 61.2% [46.2%, 74.8%]. The CHR rate change from baseline to 12 and 24 weeks is shown in Fig. 1A. The CHR rate at week 24 (61.2%) is notably higher than that at 12 months observed in the PROUD-PV study and a Phase II study by Edahiro et al. (43.1% and 51.7%, respectively) [8, 11]. The approved slow titration schema was used in the PROUD-PV study and the Phase II study by Edahiro et al. The median time to CHR was approximately 22.2 weeks or 5.6 months [95% CI: 2.9, 5.7] (Fig. 1B). Mean hematocrit, platelet, and WBC levels decreased over time from baseline to week 24: − 4.7%, − 252.6 × 109/L, and − 5.7 × 109/L, respectively, and improved to be within normal ranges at week 24. The JAK2V617F allele burden reduced in 41 out of 48 patients (85.4%). The mean change in the JAK2V617F allele burden is shown in Fig. 1C. The JAK2V617F allele burden at week 24 was 40.7% ± 27.5%. The mean change from baseline to week 24 was − 17.8%. The change of JAK2V617F allele burden in individual patients is shown in Fig. 1D. One patient achieved a complete molecular response. Partial molecular response was observed in 23 patients (46.9%) and 13 (26.5%), based on the 2009 and 2013 criteria, respectively [12]. For patients with at least 20% JAK2V617F allele burden at baseline, 13 of the 43 patients (30.2%) achieved partial molecular response, as defined by ≥ 50% reduction from the baseline.

Fig. 1
figure 1

A Bar graph showing the complete hematologic response (CHR) rates at 12 and 24 weeks. B Kaplan–Meier plot showing time to CHR. C Graph showing mean JAK2V617F allele burden change. Diamond indicates the mean value. D Waterfall plot showing the change of the JAK2V617F allele burden in individual patients. Patients who had a CHR are indicated in blue

Ropeginterferon alfa-2b was well-tolerated in the study. The targeted optimal dose of 500 μg was reached in all patients except one. Adverse events (AEs), which were mostly mild or moderate, were reported in 48 out of 49 patients. The most common AEs with an incidence ≥ 10% included an increase in alanine aminotransferase (ALT; 25/49, 51.0%) and aspartate aminotransferase (AST; 25/49, 51.0%). Most ALT and AST increases were grade 1 or grade 2, except in one patient who had a grade 3 ALT increase. However, this patient did not have a bilirubin increase or symptoms or signs such as jaundice. There were no grade 4 or 5 AEs. Grade 3 AEs that were possibly drug-related occurred in seven of the 49 patients (14.3%), which were all resolved except one patient who had grade 3 gamma glutamyl transferase increase recovering to the grade 2 level. No bilirubin levels at grade 2 or above were observed. No AEs led to treatment discontinuation. Serious AEs (SAE) that were possibly treatment-related were reported in two patients (4.1%). One patient experienced grade 3 ALT and grade 2 AST increases without elevated bilirubin or clinical symptoms at the dose of 500 μg. The patient was admitted to hospital for further check-up, and therefore reported to have an SAE. The dose was reduced to 350 μg and then to 250 μg, leading to the normalization of the aminotransferases. The dose was then adjusted and maintained at 350 μg. The second case was a 64-year-old patient experiencing an SAE of grade 3 pneumonia at the dose of 500 μg. The patient recovered before the next visit without any action taken on the dose. The common AEs occurring in ≥ 10% of patients are summarized in Table 1.

Table 1 Treatment-emergent adverse events (TEAEs) occurring in ≥ 10% of patients

In conclusion, ropeginterferon alfa-2b administered at the 250–350–500 µg dosing regimen shows tolerability, safety, efficacy and molecular response in Chinese patients with PV. The results indicate that ropeginterferon alfa-2b at the 250–350–500 µg dosing regimen is highly effective and well-tolerated. The data provides a treatment option for helping ensure optimal clinical treatment and care of patients with PV. Long-term treatment and follow-up are planned to assess patient progression-free and overall survival.

Availability of data and materials

The data will be available to external researchers upon reasonable request to PharmaEssentia after ropeginterferon alfa-2b has acquired marketing approval for polycythemia vera treatment in China.


  1. Griesshammer M, Kiladjian J-J, Besses C. Thromboembolic events in polycythemia vera. Ann Hematol. 2019;98:1071–82.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Huang YW, Qin A, Fang J, Wang T-F, Tsai C-W, Lin K-C, et al. Novel long-acting ropeginterferon alfa-2b: pharmacokinetics, pharmacodynamics, and safety in a phase I clinical trial. Br J Clin Pharmacol. 2022;88:2396–407.

    Article  CAS  PubMed  Google Scholar 

  3. Lin HH, Hsu SJ, Lu SN, Chuang WL, Hsu CW, Chien RN, et al. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: pharmacokinetics, safety, and preliminary efficacy. JGH Open. 2021;5:929–40.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Miyachi N, Zagrijtschuk O, Kang L, Yonezu K, Qin A. Pharmacokinetics and pharmacodynamics of ropeginterferon alfa-2b in healthy Japanese and caucasian subjects after single subcutaneous administration. Clin Drug Investig. 2021;41:391–404.

    Article  CAS  PubMed  Google Scholar 

  5. Chen CY, Chuang WL, Qin A, Zhang WH, Zhu LY, Zhang GQ, et al. A phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C. JGH Open. 2022;6:782–91.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Huang YW, Tsai CY, Tsai CW, Wang W, Zhang J, Qin A, et al. Pharmacokinetics and pharmacodynamics of novel long-acting ropeginterferon alfa-2b in healthy Chinese subjects. Adv Ther. 2021;38:4756–70.

    Article  CAS  PubMed  Google Scholar 

  7. Verstovsek S, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, et al. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022;18:2999–3009.

    Article  CAS  PubMed  Google Scholar 

  8. Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomized, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196–208.

    Article  PubMed  Google Scholar 

  9. Qin A, Urbanski RW, Yu L, Ahmed T, Mascarenhas J. An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: an overview of previous and ongoing studies with perspectives on the future. Front Oncol. 2023;13:1109866.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Jin J, Qin A, Zhang L, Shen W, Wang W, Zhang J, et al. A phase 2 trial to assess the efficacy and safety of ropeginterferon alfa-2b in Chinese patients with polycythemia vera. Future Oncol. 2023;19:753–61. 

    Article  PubMed  Google Scholar 

  11. Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, et al. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol. 2022;116:215–27.

    Article  CAS  PubMed  Google Scholar 

  12. Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121:4778–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


The authors thank all the participants and study coordinators, nurses, and other investigators involved in this study. We are grateful to the patients and their families.


The study was supported by PharmaEssentia Corporation.

Author information

Authors and Affiliations



Each author listed contributed to the work and take responsibility for the content. All authors participated in the writing and review process of the manuscript and agreed with the publication of this article. JJ, LZ, AQ, and XW participated in the initial writing of the manuscript and were involved in the design of the clinical study with clinical development colleagues at Pharmaessentia. JJ, LZ, ZS, JB, SC, MD, HZ, NX, SZ, XZ, XD, LW, PL, XZand ZX enrolled and treated patients on the trial. All authors read approved the final manuscript.

Corresponding authors

Correspondence to Jie Jin, Lei Zhang or Albert Qin.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the ethics committee or appropriate institutional review board of all the participating hospitals and clinical centers and followed the principles of the Declaration of Helsinki for all human experimental investigations. Informed consent was obtained from all patients participating in this study.

Consent for publication

Not applicable.

Competing interests

JJ, LZ, ZS, JBi, SC, MD, HZ, NX, SZ, XZ, XD, LW, PL, XZ, and ZX have no competing of interests to disclose. AQ, OZ, RU, TS are employees of PharmaEssentia Corporation. DW, WS, WW, JZ, and Yi are employees of PharmaEssentia Biotech (Beijing) Ltd.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jin, J., Zhang, L., Qin, A. et al. A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera. Exp Hematol Oncol 12, 55 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: